首页> 外国专利> METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS

METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS

机译:代谢产物仿制药和药物遗传学优化对甲氨蝶呤治疗的临床反应方法

摘要

The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.
机译:本发明提供了通过对至少一个基因的多态性进行基因型分析来优化个体对化学疗法的临床反应性的方法。本发明的方法可以进一步包括确定获自个体的样品中至少一种长链甲氨蝶呤多谷氨酸盐(MTXPG)的水平。本发明还提供了通过至少一个基因的多态性的基因型分析,产生用于预测个体对化学疗法的临床反应性的药物遗传学指数的方法。另外,本发明提供了通过计算从个体获得的样品中至少一种长链MTXPG的水平来优化个体的化学疗法的治疗功效的方法。

著录项

  • 公开/公告号US2009197267A1

    专利类型

  • 公开/公告日2009-08-06

    原文格式PDF

  • 申请/专利权人 THIERRY DERVIEUX;MICHAEL WALSH;

    申请/专利号US20080191287

  • 发明设计人 THIERRY DERVIEUX;MICHAEL WALSH;

    申请日2008-08-13

  • 分类号C12Q1/68;

  • 国家 US

  • 入库时间 2022-08-21 19:32:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号